BioSpace News Archive

Epsilogen, a global leader in the development of immunoglobulin E antibodies to treat cancer, notes the publication of the final phase I data from the first ever clinical trial of an IgE antibody therapeutic in Nature Communications.

MetaSight Diagnostics announced their Israeli Multi-Omics Serum Screening study in collaboration with Kahn-Sagol-Maccabi, the Research and Innovation Center of Maccabi Health Services, Israel’s leading HMO, has reached a new milestone: the creation of the a comprehensive metabolomics research consisting of hundreds of thousands of de-identified serum samples.

Emergent BioSolutions Inc. will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2023, recent business developments, revenue guidance for the third quarter of 2023, and financial outlook for full year 2023.

In the second quarter, the actions we took to strengthen our supply chain and restructure the company led to improved service for customers, reduced costs across 3M, and better than expected margins and cash flow,” said Mike Roman, 3M chairman and chief executive officer.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced the appointment of Nicole Sweeny as Chief Commercial Officer.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 3, 2023, at 8:00 a.m. EDT to review business updates and its second quarter 2023 financial results.

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601 in patients with Friedreich’s ataxia (FA) to proceed to a 50 mg cohort in which participants will be dosed daily for the first 14 days, and then every other day until day 28.

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2023 financial results and provide a business update on Thursday, August 3, after the close of the U.S. financial markets.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced its collaboration with VELL Health, a technology leader in wellness and holistic health, to introduce a groundbreaking holistic health and wellness application for people with Type 2 Diabetes in Guyana.

908 Devices Inc. today announced it will report financial results for the second quarter 2023 before market open on Tuesday, August 8, 2023.